These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38778479)

  • 1. Dynamic Risk Model for the Medical Treatment of Graves' Hyperthyroidism according to Treatment Duration.
    Jin M; Kim CA; Jeon MJ; Kim WB; Kim TY; Kim WG
    Endocrinol Metab (Seoul); 2024 Aug; 39(4):579-589. PubMed ID: 38778479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.
    Jin M; Jang A; Kim CA; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36826832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative change of thyroid stimulating hormone receptor antibody level: possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy.
    Sugino K; Mimura T; Ozaki O; Iwasaki H; Wada N; Matsumoto A; Ito K
    World J Surg; 1996 Sep; 20(7):801-6; discussion 806-7. PubMed ID: 8678954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
    Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
    Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Early-Pregnancy Antithyroid Drug Withdrawal in Graves' Disease: A Preliminary Prospective Follow-Up Study.
    Hou X; Guan H; Sun S; Shi Y; Li C; Liu A; Li Y; Gao X; Hou Y; Yang Y; Li Y; Shan Z; Teng W
    Thyroid; 2022 Aug; 32(8):983-989. PubMed ID: 35651276
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T; Müller B; Noth D; Bürgi U; Diem P
    Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
    Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
    Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
    J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography.
    Scappaticcio L; Trimboli P; Keller F; Imperiali M; Piccardo A; Giovanella L
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):169-178. PubMed ID: 31742747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of neonates born to women with Graves' disease: a cohort study.
    Besançon A; Beltrand J; Le Gac I; Luton D; Polak M
    Eur J Endocrinol; 2014 Jun; 170(6):855-62. PubMed ID: 24670885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.